HCV registries: what have we learned beyond the phase III trials
The chronic liver failure consortium (CLIF-C) acute-on-chronic liver failure score (CLIF-C ACLFs) and the CLIF-C acute-decompensation (AD) score (CLIF-C ADs). Their impact on clinical management of cirrhosis
AASLD and EASL guidelines: Commentary on differences and approaches to HCV care
Which DAA regime should include ribavirin?
Drug–drug interactions: what remains relevant in HCV treatment?
Real-life results of triple therapy with the combination of sofosbuvir-pegylated interferon-ribavirin for Egyptian patients with hepatitis C
Efficacy and safety of paritaprevir/r/ombitasvir/dasabuvir ± ribavirin in genotype 1 HCV infected patients treated in real life settings (AMBER study)
Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a compassionate use program
Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective SOLAR 2 trial
Treatment of HCV in patients with renal failure
Treatment of patients with decompensated liver cirrhosis: who benefits, who deteriorates, where is the point of no return?
Anti-viral management post liver transplantation
What have we learned since the identification of the HBV entry receptor NTCP?
New drug targets for hepatitis B virus and clinical data from phase I/II studies
HDV replication and putative drug targets
Novel therapies for NASH: what is on the horizon?
The current and future medical treatment of NASH: from vitamin E to Farnesoid X Receptor (FXR) agonists
Which treatments and endpoints for NASH trials are clinically relevant?
Which drugs should be used to treat diabetes in cirrhotic patients?
Treatment algorithm for portal and mesenteric vein thrombosis in cirrhosis
Management of severe ascites: intraperitoneal alfapump versus TIPS
HCC surveillance in patients who regressed from cirrhosis
Transarterial chemoembolisation: what is the best protocol?
Which patients can be considered for SIRT?
When to stop nucleos(t)ide analogues in chronic hepatitis B
HBV Combination therapy: interferon and nucs
Nephroprotective role of telbuvidine: when is it clinically relevant?
Resistance associated variants and chimera: to what extent do they matter?
Treatment options in patients who have failed DAA regimens
Which anti-HCV drugs will be approved after the VHC 2015?
Can simple easily reproducible biochemical tests replace the costly elastography in diagnosis of liver cirrhosis in chronic hepatitis C patients?
Agreement of indirect serum markers of liver fibrosis with liver biopsy results in chronic hepatitis C patients
Noninvasive assessment of liver fibrosis in hepatitis C: acoustic radiation force impulse imaging (shear wave elastography) and liver fibrosis biomarkers versus liver biopsy
Non-invasive liver fibrosis scores: do they also predict antiviral treatment response, decompensation, hepatocellular carcinoma and significant liver related adverse events?
Watch and wait – chronic hepatitis C patients before the era of interferon-free therapy in Germany
Prevalence and clinical outcome of post transfusion hepatitis C in young and adults
Viral load dynamics in patients with chronic hepatitis C
A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection: the Phase 3 ION-4 study
Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment
Efficacy and safety of a 12-week simeprevir plus peginterferon/ribavirin regimen in treatment-naïve HCV genotype 4-infected patients with mild-to-moderate fibrosis
Genotype 3 HCV infection, lower CD4 cell count and higher liver stiffness are related with bone mineral reduction in HIV/HCV co-infected patients (MASTER cohort)
Quacks are quick regarding management of viral infections (HBV, HCV) mainly in rural (desert) areas of Pakistan
Sustained virologic response rates in HCV genotype 1-infected patients treated for 8 weeks with ombitasvir/paritaprevir/r and dasabuvir with ribavirin
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients
Does Metformin improve sustained virological response in patients with chronic hepatitis C?
Serum biomarkers for monitoring pegylated interferon- α plus ribavirin therapy response in chronic hepatitis C patients
Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program
All-oral 12-week treatment with daclatasvir and sofosbuvir in treatment-experienced patients infected with HCV genotype 3: a subanalysis of the ALLY-3 phase 3 study
Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: phase 3 ALLY-1 study
Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1–4 in HIV-HCV coinfection: the ALLY-2 study
Recovery of HCV-like viruses from naïve MDBK cell line inoculated with rabbit and hare DNA
An outbreak of acute HCV infection with genotype 1a in a Haemodialysis Unit in Kocaeli, Turkey
Bioinformatic analysis of codon usage and phylogenetic relationships of different genotypes of hepatitis C virus
A new role for CD4+CD25+ regulatory T cells in promoting development of fibrosis in HCV nonstructural 3/4A transgenic mice
Profile of chemokines, circulating microparticles and biological systems approach in patients with chronic HCV infection before and during triple therapy
Gene expression profiling of human oxidative stress and antioxidant genes in patients with hepatitis C virus induced liver fibrosis
High expression of indoleamine 2,3-dioxygenase in cirrhotic livers of HCV patients
The use of terminal restriction fragment length polymorphism for the evaluation of antiviral resistant hepatitis B virus subpopulations in patients with chronic hepatitis B
Inactive hepatitis B virus carrier and HBeAg negative chronic hepatitis B patient's serum cytokeratin 18 and quantitative HBsAg levels
HBV-linked chronic inflammation and hepatocellular carcinomas in Arctic natives might be triggered by elevated body burden dioxin
Non-responders to hepatitis B vaccine among Egyptian healthcare workers: a pilot study
Safety and immunogenicity of 2 intramuscular double and high doses hepatitis B vaccine regimen in hemodialysis patients: a randomized controlled trial
Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C HBV-infected patients in North China
The rtI233V of hepatitis B virus may serve as a compensatory mutation associated with adefovir resistance
Characterization of novel hepatitis B virus (HBV) preS/S-gene mutations from a patient with occult HBV infection
Annual Viral Hepatitis Surveillance in Kenya: outcome of a year survey in 2014
Association of IL-18 and CD24 gene polymorphism with risk of HBV infection in Indian population
Relationship between TLR3, Th1/Th2 cytokine and responsiveness to hepatitis B vaccine of infants born to HBsAg positive mothers
Coumarin labeling of hepatitis B virus
Multidisciplinary approach to the trans-activation of human Hepatitis B Virus by body burden dioxin or dioxin-like polychlorinated biphenyls
Study of mutations in hepatitis B complete viral genome in chronic hepatitis B patients, from Southeast of Caspian Sea, Iran
Possible interaction of HBx protein with ubiquitin-related proteins encoded by gene promoter regions hypermethylated in chronic hepatitis B infection
Cytotoxic T-lymphocytes and CD4 epitope mutations in pre-core/core region of hepatitis B virus in chronic hepatitis B patients in Northeast of Iran
The efficacy of hepatitis B vaccination program in Upper Egypt: flow cytometry and the evaluation of long-term immunogenicity
Model of end stage liver disease score and hepatocellular carcinoma
Hepatitis B virus might be transcriptionally activated in Southeast Asian inhabitants due to effect of food contaminated with dioxins or polychlorinated biphenyls
Hepatitis C: sustained virological response after liver transplantation
Sofosbuvir-containing regimens are better than NS3 protease inhibitors-containing regimes for genotype 1b hepatitis C in liver transplant recipients
Towards understanding pathogenesis of hepatitis E viremia in pregnant Egyptian women